Immunovant price target lowered to $38 from $45 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...
Immunovant price target lowered to $44 from $46 at Guggenheim
Guggenheim lowered the firm’s price target on Immunovant (IMVT) to $44 from $46 and keeps a Buy rating on the shares after having hosted ...